Polymorphism of dextromethorphan oxidation in a French population.
Genetically-controlled drug oxidation capacity was studied using dextromethorphan, an anti-tussive drug, as the test compound in 103 healthy white French subjects (61 males and 42 females). Phenotyping was performed using the metabolic ratio (MR) calculated as MR = 0-10 h urinary output of dextromethorphan/0-10 h urinary output of dextrorphan, after oral administration of 40 mg (113.6 mumol) of dextromethorphan hydrobromide. The log MR was bimodally distributed: 99 subjects (96.1%) were phenotyped as extensive metabolizers; they had a log MR between -3.1 and -1.1, a urinary output of dextromethorphan below 5 mumol 10 h-1 and a urinary output of dextrorphan above 20 mumol 10 h-1. Four subjects (3.9%) were phenotyped as poor metabolizers; they had a log MR between -0.5 and +0.7, a urinary output of dextromethorphan above 5 mumol 10 h-1 and a urinary out of dextrorphan below 20 mumol 10 h-1.
Larrey
D
D
Unité de Recherches de Physiopathologie Hépatique (INSERM U 24), Hôpital Beaujon, Clichy, France.
Amouyal
G
G
Tinel
M
M
Letteron
P
P
Berson
A
A
Labbe
G
G
Pessayre
D
D
D000328:Adult; D000368:Aged; D002851:Chromatography, High Pressure Liquid; D003915:Dextromethorphan / Q000378:metabolism* / Q000652:urine; D003917:Dextrorphan / Q000652:urine; D005260:Female; D005602:France; D006801:Humans; D007981:Levorphanol / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D010641:Phenotype
D003917:Dextrorphan; D007981:Levorphanol; D003915:Dextromethorphan